5570-77-4Relevant articles and documents
Synthesis of 3H, 13C,2H3,15N and 14C-labelled SCH 466036, a histamine 3 receptor antagonist
Hesk, David,Borges,Dumpit,Hendershot,Koharski,Lavey,McNamara,Voronin
, p. 36 - 41 (2015)
The synthesis of [3H]SCH 466036, [Me-3H3]SCH 466036, [13C,2H3,15N]SCH 466036 and [14C]SCH 466036 is described. [3H]SCH 466036 was prepared in two steps via Raney Ni-catalysed exchange with tritiated water. [Me-3H3]SCH 466036 was prepared in a single step from [3H]methyl iodide in 45% yield. [13C,2H3,15N]SCH 466036 was prepared in two steps from [15N] hydroxylamine and [13C,2H3]methyl iodide with an overall yield of 16%. [14C]SCH 466036 was prepared in seven steps from [14C]potassium cyanide in an overall yield of 13%.
PROCESS FOR PREPARATION OF LASMIDITAN
-
Paragraph 0186, (2020/06/01)
The present invention relates to a process for the preparation of lasmiditan, a compound of formula I, or pharmaceutically acceptable salts thereof, the process comprising reacting a compound of formula IX with N-methoxymethylamine or salt thereof to obtain a compound of formula VII; reacting the compound of formula VII with a compound of formula XIV to obtain lasmiditan or salts thereof.
TRICYCLIC DELTA OPIOID MODULATORS
-
Page 58, (2008/06/13)
The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.